文献速递类风湿关节炎

多生物标志物评分对减停TNF抑制剂类风湿关节炎患者的预测价值

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

本研究纳入171例病情稳定低活动的长病程类风湿关节炎患者,评估基线多生物标志物疾病活动度(MBDA)评分对减停TNF抑制剂后成功减量、停药、复发及影像学进展的预测价值。结果显示,在减量组中基线MBDA评分对上述临床结局均无预测作用,仅在常规治疗组中可预测重大复发(AUROC=0.72,95%CI:0.56,0.88),影像学进展轻微且未被MBDA评分预测。

要点

  • 基线MBDA评分不能预测减量组成功减停、复发或影像学进展
  • 基线MBDA评分仅在常规治疗组中预测重大复发(AUROC=0.72)
  • 该研究中影像学进展轻微,且未被MBDA评分预测

核心结论

  • 在病情活动度指导的TNF抑制剂减量策略中,基线MBDA评分对减量患者的成功减量、停药、复发、重大复发或影像学进展均无预测价值。

研究设计与样本

  • 采用18个月非劣效随机对照试验(Dutch Trial Register,NTR 3216),比较TNF抑制剂减量至停药或复发与常规治疗,纳入长病程稳定低疾病活动度RA患者。
  • 共171/180例患者有血清样本和结局数据(减量组115例,常规治疗组56例),基线测量MBDA评分,基线和18个月采用Sharp-van der Heijde评分评估影像学。

主要发现

  • 基线MBDA评分在减量组中对上述临床结局均无预测作用。
  • 基线MBDA评分在常规治疗组中可预测重大复发(AUROC=0.72,95%CI:0.56,0.88)。
  • 影像学进展轻微,且未被MBDA评分预测。

关键数值与推荐

  • 复发定义为DAS28-CRP升高>1.2,或当前DAS≥3.2时升高>0.6。
  • 重大复发定义为尽管给予治疗干预仍持续>3个月的复发。
  • 采用受试者工作特征曲线下面积(AUROC)分析基线MBDA评分的预测能力。

临床怎么用

  • 在低疾病活动度RA患者减停TNF抑制剂时,基线MBDA评分不宜单独用于预测减量成功或复发风险。
  • 常规治疗组中基线MBDA评分对重大复发有预测价值,但需进一步验证。

局限性

  • 影像学进展轻微,可能限制了对MBDA评分预测影像学进展能力的评估。
  • 常规治疗组样本量较小(56例),其预测重大复发的发现需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate the predictive value of the baseline multi-biomarker disease activity (MBDA) score in long-standing RA patients with low disease activity tapering TNF inhibitors (TNFi) for successful tapering or discontinuation, occurrence of flare and major flare, and radiographic progression. METHODS: Dose REduction Strategies of Subcutaneous TNF inhibitors (Dutch Trial Register, NTR 3216) is an 18-month non-inferiority randomized controlled trial comparing tapering of TNFi until discontinuation or flaring with usual care (UC) in long-standing RA patients with stable low disease activity. Flare was defined as DAS28-CRP increase >1.2 or >0.6 if current DAS ⩾3.2; major flare was a flare lasting >3 months, despite treatment intervention. MBDA scores were measured at baseline. Radiographs were scored at baseline and 18 months using the Sharp-van der Heijde score. The area under the receiver operating characteristic (AUROC) curve was used to analyse the capability of baseline MBDA score to predict the above-mentioned outcomes. RESULTS: Serum samples and outcomes were available for 171 of 180 patients from Dose REduction Strategies of Subcutaneous TNF inhibitors (115 tapering; 56 UC). AUROC analyses showed that baseline MBDA score was not predictive for the above-mentioned clinical outcomes in the taper group, but did predict major flare in the UC group (AUROC = 0.72, 95% CI: 0.56, 0.88). Radiographic progression was minimal and was not predicted by MDBA score. CONCLUSION: In this disease activity-guided strategy study of TNFi tapering in RA patients with low disease activity, baseline MBDA score was not predictive for successful tapering, discontinuation, flare, major flare or radiographic progression in patients who tapered TNFi.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bouman CAM, van der Maas A, van Herwaarden N, et al. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatology (Oxford). 2017. PMID: 28339738. doi:10.1093/rheumatology/kex003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。